BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhukovsky EA, Morse RJ, Maus MV. Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection. Curr Opin Immunol 2016;40:24-35. [PMID: 26963133 DOI: 10.1016/j.coi.2016.02.006] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Froning KJ, Leaver-Fay A, Wu X, Phan S, Gao L, Huang F, Pustilnik A, Bacica M, Houlihan K, Chai Q, Fitchett JR, Hendle J, Kuhlman B, Demarest SJ. Computational design of a specific heavy chain/κ light chain interface for expressing fully IgG bispecific antibodies. Protein Sci 2017;26:2021-38. [PMID: 28726352 DOI: 10.1002/pro.3240] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
2 Walseng E, Nelson CG, Qi J, Nanna AR, Roush WR, Goswami RK, Sinha SC, Burke TR Jr, Rader C. Chemically Programmed Bispecific Antibodies in Diabody Format. J Biol Chem 2016;291:19661-73. [PMID: 27445334 DOI: 10.1074/jbc.M116.745588] [Cited by in Crossref: 26] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
3 Goulet DR, Atkins WM. Considerations for the Design of Antibody-Based Therapeutics. J Pharm Sci 2020;109:74-103. [PMID: 31173761 DOI: 10.1016/j.xphs.2019.05.031] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 13.0] [Reference Citation Analysis]
4 Yasunaga M. Antibody therapeutics and immunoregulation in cancer and autoimmune disease. Semin Cancer Biol 2020;64:1-12. [PMID: 31181267 DOI: 10.1016/j.semcancer.2019.06.001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
5 Shi H, Yu F, Mao Y, Ju Q, Wu Y, Bai W, Wang P, Xu R, Jiang M, Shi J. EphA2 chimeric antigen receptor-modified T cells for the immunotherapy of esophageal squamous cell carcinoma. J Thorac Dis 2018;10:2779-88. [PMID: 29997940 DOI: 10.21037/jtd.2018.04.91] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
6 Wu J, Liu C, Tsui ST, Liu D. Second-generation inhibitors of Bruton tyrosine kinase. J Hematol Oncol 2016;9:80. [PMID: 27590878 DOI: 10.1186/s13045-016-0313-y] [Cited by in Crossref: 97] [Cited by in F6Publishing: 102] [Article Influence: 16.2] [Reference Citation Analysis]
7 Gong N, Sheppard NC, Billingsley MM, June CH, Mitchell MJ. Nanomaterials for T-cell cancer immunotherapy. Nat Nanotechnol 2021;16:25-36. [PMID: 33437036 DOI: 10.1038/s41565-020-00822-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 19.0] [Reference Citation Analysis]
8 Jiang X, Chen X, Jaiprasart P, Carpenter TJ, Zhou R, Wang W. Development of a minimal physiologically-based pharmacokinetic/pharmacodynamic model to characterize target cell depletion and cytokine release for T cell-redirecting bispecific agents in humans. Eur J Pharm Sci 2020;146:105260. [PMID: 32058058 DOI: 10.1016/j.ejps.2020.105260] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Rovatti PE, Gambacorta V, Lorentino F, Ciceri F, Vago L. Mechanisms of Leukemia Immune Evasion and Their Role in Relapse After Haploidentical Hematopoietic Cell Transplantation. Front Immunol 2020;11:147. [PMID: 32158444 DOI: 10.3389/fimmu.2020.00147] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
10 Scarfò I, Maus MV. Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment. J Immunother Cancer 2017;5:28. [PMID: 28331617 DOI: 10.1186/s40425-017-0230-9] [Cited by in Crossref: 86] [Cited by in F6Publishing: 86] [Article Influence: 17.2] [Reference Citation Analysis]
11 Warwas KM, Meyer M, Gonçalves M, Moldenhauer G, Bulbuc N, Knabe S, Luckner-Minden C, Ziegelmeier C, Heussel CP, Zörnig I, Jäger D, Momburg F. Co-Stimulatory Bispecific Antibodies Induce Enhanced T Cell Activation and Tumor Cell Killing in Breast Cancer Models. Front Immunol 2021;12:719116. [PMID: 34484225 DOI: 10.3389/fimmu.2021.719116] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Setiawan D, Brender J, Zhang Y. Recent advances in automated protein design and its future challenges. Expert Opin Drug Discov 2018;13:587-604. [PMID: 29695210 DOI: 10.1080/17460441.2018.1465922] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
13 Chiu ML, Goulet DR, Teplyakov A, Gilliland GL. Antibody Structure and Function: The Basis for Engineering Therapeutics. Antibodies (Basel) 2019;8:E55. [PMID: 31816964 DOI: 10.3390/antib8040055] [Cited by in Crossref: 57] [Cited by in F6Publishing: 36] [Article Influence: 19.0] [Reference Citation Analysis]
14 Huang S, van Duijnhoven SMJ, Sijts AJAM, van Elsas A. Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy. J Cancer Res Clin Oncol 2020;146:3111-22. [PMID: 32989604 DOI: 10.1007/s00432-020-03404-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
15 Ellmark P, Mangsbo SM, Furebring C, Norlén P, Tötterman TH. Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation. Cancer Immunol Immunother 2017;66:1-7. [PMID: 27714433 DOI: 10.1007/s00262-016-1909-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
16 Goonetilleke N, Clutton G, Swanstrom R, Joseph SB. Blocking Formation of the Stable HIV Reservoir: A New Perspective for HIV-1 Cure. Front Immunol 2019;10:1966. [PMID: 31507594 DOI: 10.3389/fimmu.2019.01966] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
17 Peyrin-biroulet L, Demarest S, Nirula A. Bispecific antibodies: The next generation of targeted inflammatory bowel disease therapies. Autoimmunity Reviews 2019;18:123-8. [DOI: 10.1016/j.autrev.2018.07.014] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
18 Yefremova Y, Danquah BD, Opuni KF, El-Kased R, Koy C, Glocker MO. Mass spectrometric characterization of protein structures and protein complexes in condensed and gas phase. Eur J Mass Spectrom (Chichester) 2017;23:445-59. [PMID: 29183193 DOI: 10.1177/1469066717722256] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
19 Berahovich R, Zhou H, Xu S, Wei Y, Guan J, Guan J, Harto H, Fu S, Yang K, Zhu S, Li L, Wu L, Golubovskaya V. CAR-T Cells Based on Novel BCMA Monoclonal Antibody Block Multiple Myeloma Cell Growth. Cancers (Basel) 2018;10:E323. [PMID: 30208593 DOI: 10.3390/cancers10090323] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
20 Naran K, Nundalall T, Chetty S, Barth S. Principles of Immunotherapy: Implications for Treatment Strategies in Cancer and Infectious Diseases. Front Microbiol 2018;9:3158. [PMID: 30622524 DOI: 10.3389/fmicb.2018.03158] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 6.5] [Reference Citation Analysis]
21 Egen JG, Ouyang W, Wu LC. Human Anti-tumor Immunity: Insights from Immunotherapy Clinical Trials. Immunity 2020;52:36-54. [DOI: 10.1016/j.immuni.2019.12.010] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 22.5] [Reference Citation Analysis]
22 Kunadt D, Stölzel F. Effective Immunosurveillance After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia. Cancer Manag Res 2021;13:7411-27. [PMID: 34594134 DOI: 10.2147/CMAR.S261721] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Skokos D, Waite JC, Haber L, Crawford A, Hermann A, Ullman E, Slim R, Godin S, Ajithdoss D, Ye X, Wang B, Wu Q, Ramos I, Pawashe A, Canova L, Vazzana K, Ram P, Herlihy E, Ahmed H, Oswald E, Golubov J, Poon P, Havel L, Chiu D, Lazo M, Provoncha K, Yu K, Kim J, Warsaw JJ, Stokes Oristian N, Siao CJ, Dudgeon D, Huang T, Potocky T, Martin J, MacDonald D, Oyejide A, Rafique A, Poueymirou W, Kirshner JR, Smith E, Olson W, Lin J, Thurston G, Sleeman MA, Murphy AJ, Yancopoulos GD. A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies. Sci Transl Med 2020;12:eaaw7888. [PMID: 31915305 DOI: 10.1126/scitranslmed.aaw7888] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 22.0] [Reference Citation Analysis]
24 Strohl WR. Current progress in innovative engineered antibodies. Protein Cell 2018;9:86-120. [PMID: 28822103 DOI: 10.1007/s13238-017-0457-8] [Cited by in Crossref: 151] [Cited by in F6Publishing: 123] [Article Influence: 30.2] [Reference Citation Analysis]
25 Corraliza-Gorjón I, Somovilla-Crespo B, Santamaria S, Garcia-Sanz JA, Kremer L. New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness. Front Immunol 2017;8:1804. [PMID: 29312320 DOI: 10.3389/fimmu.2017.01804] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 6.6] [Reference Citation Analysis]
26 Ellerman D. Bispecific T-cell engagers: Towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety. Methods 2019;154:102-17. [PMID: 30395966 DOI: 10.1016/j.ymeth.2018.10.026] [Cited by in Crossref: 70] [Cited by in F6Publishing: 54] [Article Influence: 17.5] [Reference Citation Analysis]
27 Seifert O, Rau A, Beha N, Richter F, Kontermann RE. Diabody-Ig: a novel platform for the generation of multivalent and multispecific antibody molecules. MAbs 2019;11:919-29. [PMID: 30951400 DOI: 10.1080/19420862.2019.1603024] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
28 Golubovskaya V, Zhou H, Li F, Berahovich R, Sun J, Valentine M, Xu S, Harto H, Sienkiewicz J, Huang Y, Wu L. Novel CS1 CAR-T Cells and Bispecific CS1-BCMA CAR-T Cells Effectively Target Multiple Myeloma. Biomedicines 2021;9:1422. [PMID: 34680541 DOI: 10.3390/biomedicines9101422] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Salhotra A, Stein AS. Role of Radiation Based Conditioning Regimens in Patients With High-Risk AML Undergoing Allogenic Transplantation in Remission or Active Disease and Mechanisms of Post-Transplant Relapse. Front Oncol 2022;12:802648. [PMID: 35242706 DOI: 10.3389/fonc.2022.802648] [Reference Citation Analysis]
30 Wu J, Zhang M, Liu D. Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside. Oncotarget 2017;8:7201-7. [PMID: 27776353 DOI: 10.18632/oncotarget.12786] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
31 Hegde PS, Chen DS. Top 10 Challenges in Cancer Immunotherapy. Immunity 2020;52:17-35. [PMID: 31940268 DOI: 10.1016/j.immuni.2019.12.011] [Cited by in Crossref: 264] [Cited by in F6Publishing: 248] [Article Influence: 132.0] [Reference Citation Analysis]
32 Runcie K, Budman DR, John V, Seetharamu N. Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics. Mol Med 2018;24:50. [PMID: 30249178 DOI: 10.1186/s10020-018-0051-4] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 13.5] [Reference Citation Analysis]
33 Han C, Choi BK, Kim SH, Sim SJ, Han S, Park B, Tsuchiya Y, Takahashi M, Kim YH, Eom HS, Kitaguchi T, Ueda H, Kwon BS. Polymorphic Region-Specific Antibody for Evaluation of Affinity-Associated Profile of Chimeric Antigen Receptor. Mol Ther Oncolytics 2020;17:293-305. [PMID: 32368617 DOI: 10.1016/j.omto.2020.04.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 Wang Y, Luo F, Yang J, Zhao C, Chu Y. New Chimeric Antigen Receptor Design for Solid Tumors. Front Immunol 2017;8:1934. [PMID: 29312360 DOI: 10.3389/fimmu.2017.01934] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
35 Zirngibl F, Ivasko SM, Grunewald L, Klaus A, Schwiebert S, Ruf P, Lindhofer H, Astrahantseff K, Andersch L, Schulte JH, Lode HN, Eggert A, Anders K, Hundsdoerfer P, Künkele A. GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma. J Immunother Cancer 2021;9:e002923. [PMID: 34285106 DOI: 10.1136/jitc-2021-002923] [Reference Citation Analysis]
36 Fellermeier-Kopf S, Gieseke F, Sahin U, Müller D, Pfizenmaier K, Kontermann RE. Duokines: a novel class of dual-acting co-stimulatory molecules acting in cis or trans. Oncoimmunology 2018;7:e1471442. [PMID: 30228940 DOI: 10.1080/2162402X.2018.1471442] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
37 Nair-Gupta P, Rudnick SI, Luistro L, Smith M, McDaid R, Li Y, Pillarisetti K, Joseph J, Heidrich B, Packman K, Attar R, Gaudet F. Blockade of VLA4 sensitizes leukemic and myeloma tumor cells to CD3 redirection in the bone marrow microenvironment. Blood Cancer J 2020;10:65. [PMID: 32483120 DOI: 10.1038/s41408-020-0331-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
38 Horenstein AL, Chillemi A, Quarona V, Zito A, Mariani V, Faini AC, Morandi F, Schiavoni I, Ausiello CM, Malavasi F. Antibody mimicry, receptors and clinical applications. Hum Antibodies 2017;25:75-85. [PMID: 28035914 DOI: 10.3233/HAB-160305] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
39 Alhallak K, Sun J, Jeske A, Park C, Yavner J, Bash H, Lubben B, Adebayo O, Khaskiah A, Azab AK. Bispecific T Cell Engagers for the Treatment of Multiple Myeloma: Achievements and Challenges. Cancers (Basel) 2021;13:2853. [PMID: 34201007 DOI: 10.3390/cancers13122853] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
40 Jiang H, Xu W, Liu R, Gupta B, Kilgore B, Du Z, Yang X. Characterization of Bispecific Antibody Production in Cell Cultures by Unique Mixed Mode Size Exclusion Chromatography. Anal Chem 2020;92:9312-21. [DOI: 10.1021/acs.analchem.0c01641] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
41 Dickopf S, Lauer ME, Ringler P, Spick C, Kern P, Brinkmann U. Highly flexible, IgG-shaped, trivalent antibodies effectively target tumor cells and induce T cell-mediated killing. Biol Chem 2019;400:343-50. [PMID: 30763031 DOI: 10.1515/hsz-2018-0338] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
42 Wang Y, Luong M, Guadiz C, Zhang M, Gorovits B. Addressing soluble target interference in the development of a functional assay for the detection of neutralizing antibodies against a BCMA-CD3 bispecific antibody. J Immunol Methods 2019;474:112642. [PMID: 31400410 DOI: 10.1016/j.jim.2019.112642] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
43 Chapoval AI, Chapoval SP, Shcherbakova NS, Shcherbakov DN. Immune Checkpoints of the B7 Family. Part 2. Representatives of the B7 Family B7-H3, B7-H4, B7-H5, B7-H6, B7-H7, and ILDR2 and Their Receptors. Russ J Bioorg Chem 2019;45:321-34. [DOI: 10.1134/s1068162019050091] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
44 Astorga-Gamaza A, Vitali M, Borrajo ML, Suárez-López R, Jaime C, Bastus N, Serra-Peinado C, Luque-Ballesteros L, Blanch-Lombarte O, Prado JG, Lorente J, Pumarola F, Pellicer M, Falcó V, Genescà M, Puntes V, Buzon MJ. Antibody cooperative adsorption onto AuNPs and its exploitation to force natural killer cells to kill HIV-infected T cells. Nano Today 2021;36:101056. [PMID: 34394703 DOI: 10.1016/j.nantod.2020.101056] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
45 Kim HS, Dunshee DR, Yee A, Tong RK, Kim I, Farahi F, Hongo JA, Ernst JA, Sonoda J, Spiess C. Tethered-variable CL bispecific IgG: an antibody platform for rapid bispecific antibody screening. Protein Eng Des Sel 2017;30:627-37. [PMID: 28985411 DOI: 10.1093/protein/gzx034] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
46 Jiang X, Chen X, Carpenter TJ, Wang J, Zhou R, Davis HM, Heald DL, Wang W. Development of a Target cell-Biologics-Effector cell (TBE) complex-based cell killing model to characterize target cell depletion by T cell redirecting bispecific agents. MAbs 2018;10:876-89. [PMID: 29985776 DOI: 10.1080/19420862.2018.1480299] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
47 Strohl WR, Naso M. Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells. Antibodies (Basel) 2019;8:E41. [PMID: 31544847 DOI: 10.3390/antib8030041] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 14.3] [Reference Citation Analysis]
48 Goulet DR, Orcutt SJ, Zwolak A, Rispens T, Labrijn AF, de Jong RN, Atkins WM, Chiu ML. Kinetic mechanism of controlled Fab-arm exchange for the formation of bispecific immunoglobulin G1 antibodies. J Biol Chem 2018;293:651-61. [PMID: 29150443 DOI: 10.1074/jbc.RA117.000303] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
49 Sioud M. Phage Display Libraries: From Binders to Targeted Drug Delivery and Human Therapeutics. Mol Biotechnol 2019;61:286-303. [DOI: 10.1007/s12033-019-00156-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 7.7] [Reference Citation Analysis]
50 Wu HW, Zhao YM, Huang H. [Mechanism of relapse and its therapeutic strategies after allogeneic hematopoietic stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi 2021;42:869-77. [PMID: 34788930 DOI: 10.3760/cma.j.issn.0253-2727.2021.10.014] [Reference Citation Analysis]
51 Kandari D, Bhatnagar R. Antibody engineering and its therapeutic applications. Int Rev Immunol 2021;:1-28. [PMID: 34355613 DOI: 10.1080/08830185.2021.1960986] [Reference Citation Analysis]
52 Xie X, Lee J, Iwase T, Kai M, Ueno NT. Emerging drug targets for triple-negative breast cancer: A guided tour of the preclinical landscape. Expert Opin Ther Targets 2022. [PMID: 35574694 DOI: 10.1080/14728222.2022.2077188] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
53 Nakayama M, Komiya S, Fujiwara K, Horisawa K, Doi N. In vitro selection of bispecific diabody fragments using covalent bicistronic DNA display. Biochem Biophys Res Commun 2016;478:606-11. [PMID: 27473655 DOI: 10.1016/j.bbrc.2016.07.113] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
54 Brinkmann U, Kontermann RE. The making of bispecific antibodies. MAbs 2017;9:182-212. [PMID: 28071970 DOI: 10.1080/19420862.2016.1268307] [Cited by in Crossref: 370] [Cited by in F6Publishing: 339] [Article Influence: 74.0] [Reference Citation Analysis]
55 Waaijer SJH, Warnders FJ, Stienen S, Friedrich M, Sternjak A, Cheung HK, van Scheltinga AGTT, Schröder CP, de Vries EGE, Lub-de Hooge MN. Molecular Imaging of Radiolabeled Bispecific T-Cell Engager 89Zr-AMG211 Targeting CEA-Positive Tumors. Clin Cancer Res 2018;24:4988-96. [PMID: 29980531 DOI: 10.1158/1078-0432.CCR-18-0786] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
56 Waite JC, Wang B, Haber L, Hermann A, Ullman E, Ye X, Dudgeon D, Slim R, Ajithdoss DK, Godin SJ, Ramos I, Wu Q, Oswald E, Poon P, Golubov J, Grote D, Stella J, Pawashe A, Finney J, Herlihy E, Ahmed H, Kamat V, Dorvilliers A, Navarro E, Xiao J, Kim J, Yang SN, Warsaw J, Lett C, Canova L, Schulenburg T, Foster R, Krueger P, Garnova E, Rafique A, Babb R, Chen G, Stokes Oristian N, Siao CJ, Daly C, Gurer C, Martin J, Macdonald L, MacDonald D, Poueymirou W, Smith E, Lowy I, Thurston G, Olson W, Lin JC, Sleeman MA, Yancopoulos GD, Murphy AJ, Skokos D. Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy. Sci Transl Med 2020;12:eaba2325. [PMID: 32581132 DOI: 10.1126/scitranslmed.aba2325] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 17.0] [Reference Citation Analysis]
57 Amir Taghavi B, Alizadeh N, Saeedi H, Karim Ahangar N, Derakhshani A, Hajiasgharzadeh K, Silvestris N, Baradaran B, Brunetti O. Targeted Therapy of B7 Family Checkpoints as an Innovative Approach to Overcome Cancer Therapy Resistance: A Review from Chemotherapy to Immunotherapy. Molecules 2022;27:3545. [PMID: 35684481 DOI: 10.3390/molecules27113545] [Reference Citation Analysis]
58 Carter PJ, Lazar GA. Next generation antibody drugs: pursuit of the 'high-hanging fruit'. Nat Rev Drug Discov 2018;17:197-223. [DOI: 10.1038/nrd.2017.227] [Cited by in Crossref: 322] [Cited by in F6Publishing: 296] [Article Influence: 64.4] [Reference Citation Analysis]